Satellos Bioscience Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Francis Gleeson
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 65 Front Street East Toronto ON Canada M5E 1B5
- IPO Date
- Aug 3, 2012
- CIK
- 0001421642
- Website
- satellos.com
- Similar Companies
- Business
- Satellos Bioscience Inc specializes in developing novel small molecule therapeutics aimed at regenerating muscle to treat Duchenne muscular dystrophy (DMD) and other severe muscle degenerative diseases. The company's core products include SAT-3247, an oral small molecule inhibitor targeting AP2-associated kinase 1 (AAK1) that restores muscle stem cell polarity and promotes muscle regeneration. Satellos also employs its proprietary MyoReGenX discovery platform to identify regulatory pathways and develop therapeutics for various muscle disorders characterized by impaired muscle stem cell function. The company operates primarily in Canada and is advancing clinical programs globally, targeting rare muscle diseases and other muscle wasting conditions. Founded in 2008 and headquartered in Toronto, Canada, Satellos Bioscience conducts research, development, and clinical trials to develop disease-modifying treatments for muscle regeneration. Recently, Satellos has made significant progress in the clinical development of SAT-3247. It reported positive Phase 1b clinical data showing safety, tolerability, and functional improvements such as doubling grip strength in adult DMD patients. The company is preparing submissions to initiate a global Phase 2 randomized, placebo-controlled clinical trial in children with Duchenne, with an Investigational New Drug (IND) application submitted to the U.S. FDA and regulatory authorities in other countries in 2025. Satellos also expanded its leadership team with the appointment of a new Chief Medical Officer and added an experienced M&A expert to its board. Furthermore, Satellos maintains strategic partnerships through its subsidiary Amphotericin B Technologies Inc., including a joint venture developing oral cannabidiol formulations in mental health indications. The company ended the second quarter of 2025 with a strong cash position to support ongoing clinical development and is actively advancing its pipeline and global regulatory efforts.
Company News
Satellos Granted Composition of Matter Patent for Forazapadin
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
Satellos to Present at the 31st Annual Congress of the World Muscle Society
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
Satellos to Participate in Upcoming Investor Conferences
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
Satellos to Present Clinical Program Updates at ICNMD 2026
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
Satellos to Participate in Upcoming Investor Conferences
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
Satellos to Participate in Upcoming Investor Conferences
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares